NASD · Healthcare · Biotechnology · USA
Moderna Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Moderna is a mRNA medicine company that develops vaccine and therapeutic candidates across infectious disease, oncology, and rare disease. It commercializes three products: Spikevax and mNEXSPIKE COVID vaccines, and mRESVIA, an RSV vaccine. The company advances a pipeline of development candidates including oncology therapies, infectious disease vaccines, and rare disease treatments.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Moderna Inc stock.
Overvalued: intrinsic value $7.15 per share, market price $242.08, margin of safety -3284.0% (as of 2026-10-20).
Its liquidation floor, current assets minus every liability, values the shares at $7.15; the price of $242.08 is 3284% above that value.
Leak Score: 27/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
132 more in this industry show a wider margin of safety.
MRNA is overvalued (as of the 2026-10-20 close). Its liquidation floor, current assets minus every liability, values the shares at $7.15; the price of $242.08 is 3284% above that value.
$7.15 per share (as of the 2026-10-20 close), against a market price of $242.08. That is a margin of safety of -3284.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
27 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.